B2M and plasma cell myeloma: Biomarkers primarily in the blood (e.g., IgG for myeloma) but occasionally in the urine (e.g., Beta-2 microglobulin for leukaemia) or in the cerebrospinal fluid (e.g., fibrin for bladder cancer) can assist in diagnosis and monitoring.